A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
Status:
NOT_YET_RECRUITING
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.